Gan, Lee Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide Injection for Overweight or Obesity Veröffentlicht: 07.08.2025 um 18:07 Uhr, prnewswire.co.uk Gan & Lee Pharmaceuticals Denmark Finland Germany Netherlands Sweden United Kingdom New Jersey China Austria View original content:https://www.prnewswire.co.uk/news-releases/gan--lee-pharmaceuticals-announced-first-participant-dosed-in-the-us-phase-2-clinical-study-of-bofanglutide-gzr18-injection-for-overweight-or-obesity-302397207.html en | boerse | 67935218 |
